1) Nausea and vomiting Nausea is the most common side effect of Wegovy, with at least 25% of participants on GLP-1s experiencing it, with some studies showing up to 53% of participants reporting nausea at least once
In the pre-specified in-study analysis based on pooled 9 mg and 12 mg retatrutide groups, 44 participants receiving retatrutide experienced a MACE-5 event, defined as all-cause death, myocardial infarction, stroke, heart failure event, or coronary revascularization, compared with 52 participants receiving placebo, corresponding to a hazard ratio of 0.82 (95% CI: 0.55-1.22)
Treatment benefits fade rapidly, with only 6.2% of patients maintaining effects at 6 months post-treatment
Before reviewing, I signed up with Fifty 410, recorded the process, and gathered the key info you need to see if its a good fit